Modelling α-Synuclein Aggregation and Neurodegeneration with Fibril Seeds in Primary Cultures of Mouse Dopaminergic Neurons.
Parkinson disease
cell culture model
dopamine neurons
fibril seeds
neurodegeneration
protein aggregation
α-Synuclein
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
13 05 2022
13 05 2022
Historique:
received:
04
04
2022
revised:
10
05
2022
accepted:
12
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
To model α-Synuclein (αS) aggregation and neurodegeneration in Parkinson's disease (PD), we established cultures of mouse midbrain dopamine (DA) neurons and chronically exposed them to fibrils 91 (F91) generated from recombinant human αS. We found that F91 have an exquisite propensity to seed the aggregation of endogenous αS in DA neurons when compared to other neurons in midbrain cultures. Until two weeks post-exposure, somal aggregation in DA neurons increased with F91 concentrations (0.01-0.75 μM) and the time elapsed since the initiation of seeding, with, however, no evidence of DA cell loss within this time interval. Neither toxin-induced mitochondrial deficits nor genetically induced loss of mitochondrial quality control mechanisms promoted F91-mediated αS aggregation or neurodegeneration under these conditions. Yet, a significant loss of DA neurons (~30%) was detectable three weeks after exposure to F91 (0.5 μM), i.e., at a time point where somal aggregation reached a plateau. This loss was preceded by early deficits in DA uptake. Unlike αS aggregation, the loss of DA neurons was prevented by treatment with GDNF, suggesting that αS aggregation in DA neurons may induce a form of cell death mimicking a state of trophic factor deprivation. Overall, our model system may be useful for exploring PD-related pathomechanisms and for testing molecules of therapeutic interest for this disorder.
Identifiants
pubmed: 35626675
pii: cells11101640
doi: 10.3390/cells11101640
pmc: PMC9139621
pii:
doi:
Substances chimiques
alpha-Synuclein
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Commun. 2021 Jun 21;12(1):3817
pubmed: 34155194
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5
pubmed: 19651612
Mol Neurodegener. 2015 Jun 23;10:23
pubmed: 26099628
J Comp Neurol. 2018 Aug 15;526(12):1978-1990
pubmed: 29888794
J Neurosci Methods. 2015 Nov 30;255:38-51
pubmed: 26247888
Nat Commun. 2018 Jun 12;9(1):2293
pubmed: 29895861
Nat Rev Neurosci. 2017 Mar 17;18(4):251-259
pubmed: 28303016
FEBS Lett. 2015 Dec 21;589(24 Pt A):3760-72
pubmed: 26555190
Nat Cell Biol. 2002 Feb;4(2):160-4
pubmed: 11813001
Int J Mol Sci. 2020 Oct 28;21(21):
pubmed: 33126694
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4971-4982
pubmed: 32075919
J Biol Chem. 2004 Apr 9;279(15):15240-7
pubmed: 14742448
J Neurochem. 1990 Apr;54(4):1102-9
pubmed: 1968953
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):E4016-25
pubmed: 24082145
FEBS J. 2005 Aug;272(16):4023-33
pubmed: 16098186
ACS Chem Neurosci. 2020 Nov 4;11(21):3541-3548
pubmed: 33080132
Neurobiol Dis. 2020 Feb;134:104623
pubmed: 31628991
J Neurochem. 2019 Sep;150(5):605-611
pubmed: 31152606
Nature. 2021 Nov;599(7886):650-656
pubmed: 34732887
Mol Biol Cell. 2014 Dec 15;25(25):4010-23
pubmed: 25298402
Sci Adv. 2020 Nov 11;6(46):
pubmed: 33177086
Glia. 2018 Aug;66(8):1736-1751
pubmed: 29665074
Cell Death Dis. 2015 Jul 16;6:e1820
pubmed: 26181201
JAMA Neurol. 2014 May;71(5):537-8
pubmed: 24664140
Glia. 2016 Nov;64(11):1912-24
pubmed: 27452488
Nat Commun. 2021 Mar 22;12(1):1814
pubmed: 33753734
Mov Disord. 2020 Dec;35(12):2279-2289
pubmed: 32964492
Mov Disord. 2009 Jul 30;24(10):1519-23
pubmed: 19526568
Cell Tissue Res. 2018 Jul;373(1):137-148
pubmed: 29119326
J Neurochem. 1989 Oct;53(4):1149-55
pubmed: 2788714
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73
pubmed: 9600990
J Neurochem. 2017 Jul;142(1):14-28
pubmed: 28398653
Front Neuroanat. 2014 Dec 15;8:152
pubmed: 25565977
Nature. 2016 Feb 4;530(7588):45-50
pubmed: 26808899
Nat Neurosci. 2017 May;20(5):681-689
pubmed: 28288128
Mov Disord. 2013 Jan;28(1):24-30
pubmed: 22927094
Biochim Biophys Acta. 2009 Jul;1792(7):616-24
pubmed: 18955133
Sci Rep. 2020 Mar 17;10(1):4895
pubmed: 32184415
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
J Neurochem. 1997 Oct;69(4):1499-507
pubmed: 9326279
Antioxid Redox Signal. 2016 Mar 1;24(7):376-91
pubmed: 26564470
Sci Rep. 2016 Apr 14;6:24526
pubmed: 27075649
Mol Pharmacol. 2008 Oct;74(4):980-9
pubmed: 18621927
Adv Neurol. 1987;45:317-21
pubmed: 3493630
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Mov Disord. 1999 May;14(3):417-22
pubmed: 10348463
Lancet Neurol. 2004 Aug;3(8):496-503
pubmed: 15261611
Stem Cell Reports. 2019 Feb 12;12(2):230-244
pubmed: 30639210
Acta Neuropathol Commun. 2021 Nov 24;9(1):188
pubmed: 34819159
J Neurochem. 2019 Sep;150(5):475-486
pubmed: 31269263
Science. 1980 Aug 15;209(4458):809-10
pubmed: 7403847
Nat Genet. 2009 Dec;41(12):1303-7
pubmed: 19915576
J Neurochem. 2015 Oct;135(1):4-18
pubmed: 26134497
Mov Disord. 2017 Jul;32(7):983-990
pubmed: 28520211
Biomolecules. 2015 Jul 22;5(3):1634-51
pubmed: 26287258
Biophys J. 2020 Mar 24;118(6):1301-1320
pubmed: 32059758
Front Neurol. 2018 Jun 19;9:455
pubmed: 29971039
J Neurochem. 2019 Sep;150(5):522-534
pubmed: 31254394
Neuron. 2018 Jan 3;97(1):108-124.e6
pubmed: 29249285
Science. 1993 May 21;260(5111):1130-2
pubmed: 8493557
Nat Neurosci. 2019 Jul;22(7):1099-1109
pubmed: 31235907
Acta Neuropathol. 2016 Jul;132(1):77-91
pubmed: 26839082
Acta Neuropathol. 2018 Jun;135(6):855-875
pubmed: 29502200
J Biol Chem. 2002 Feb 15;277(7):5411-7
pubmed: 11724769
Mol Neurobiol. 2022 Feb;59(2):1273-1284
pubmed: 34984585
Sci Rep. 2016 Nov 30;6:37970
pubmed: 27901068
Nature. 1998 Apr 9;392(6676):605-8
pubmed: 9560156
Front Pharmacol. 2020 Apr 23;11:356
pubmed: 32390826
Mov Disord. 2004 Feb;19(2):162-70
pubmed: 14978671
Physiol Rev. 2011 Oct;91(4):1161-218
pubmed: 22013209
Ann Neurol. 2012 Oct;72(4):517-24
pubmed: 23109146
Mol Pharmacol. 2013 Dec;84(6):888-98
pubmed: 24077968
BMC Biotechnol. 2004 Oct 15;4:23
pubmed: 15485583
Cells. 2021 Aug 22;10(8):
pubmed: 34440932
J Neurosci Methods. 2017 Mar 15;280:1-10
pubmed: 28137433
Neuropathology. 2007 Oct;27(5):494-506
pubmed: 18018486
Curr Neurol Neurosci Rep. 2012 Jun;12(3):237-42
pubmed: 22538490
Mol Neurodegener. 2020 Jan 13;15(1):5
pubmed: 31931835
Neurobiol Dis. 2019 Oct;130:104525
pubmed: 31276792
eNeuro. 2020 Aug 17;7(4):
pubmed: 32487763
J Neurochem. 2009 Jun;109(5):1348-62
pubmed: 19476547
J Neurochem. 2011 Dec;119(5):957-71
pubmed: 21434924
J Neurosci. 2002 Oct 15;22(20):8951-60
pubmed: 12388602
J Neurosci. 2012 Oct 3;32(40):14033-49
pubmed: 23035110
Neuron. 2016 May 18;90(4):675-91
pubmed: 27196972
Mol Ther. 2017 Oct 4;25(10):2231-2235
pubmed: 28522034
Acta Neuropathol. 2017 Oct;134(4):629-653
pubmed: 28527044
Front Pharmacol. 2021 Jan 11;11:617085
pubmed: 33510643